ArticleInvestigative ophthalmology & visual science2025
Accelerated Biological Aging and Genetic Pleiotropy in Age-Related Eye Diseases: A Population-Based Cohort and Integrative Genetic Analysis.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenotypic age acceleration and genetic risk synergistically increase age-related eye disease risk in the UK Biobank.Scientific reports · 2026Article
- Sugar rationing in the first 1000 days of life and risk of frailty: evidence from a natural experiment.The journal of nutrition, health & aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Age-related eye diseases (AREDs) are major causes of vision loss worldwide. Biological age acceleration (BAA) reflects systemic aging, but its relationship with AREDs and underlying genetic mechanisms remains unclear. This study investigated the combined effects of BAA and genetic risk on AREDs and blindness, and explored shared genetic pathways and potential anti-aging targets. Methods: Biological age was measured using the Klemera-Doubal method for estimating biological age (KDM-BA) and PhenoAge algorithms. We assessed the cross-sectional and prospective associations between BAA and AREDs in 297,375 participants from the UK Biobank, followed by genetic pleiotropy analysis. Results: Participants with higher BAA were more likely to experience AREDs at baseline and had an increased risk of incident AREDs during follow-up. In participants with high genetic susceptibility to AREDs, accelerated biological aging was associated with an increased risk of disease onset. Notably, we observed a significant additive interaction between BAA and genetic risk. The multi-omics integrative analysis identified 115 genetic variants with pleiotropic effects and 512 candidate genes. Notably, we identified APOE, APOC1, TOMM40, PVRL2, and BCAM as shared genes between BAA and the three AREDs. Among ARED patients, accelerated biological aging was associated with a reduction in vision-healthy life expectancy, compared to those without accelerated biological aging. Conclusions: Accelerated biological aging significantly increases ARED risk, especially in those with high genetic risk, and is linked to shorter vision-healthy life expectancy. Identifying individuals with accelerated aging may help reduce ARED risk and improve vision-healthy life expectancy. APOE, APOC1, TOMM40, PVRL2, and BCAM could be potential targets for ocular anti-aging interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.